Biotech Values

[DewDiligence]

>[IDIX] Isn't it a catch 22 for novartis? If they go ahead and license it, they have to pay the money for 200mg dose which might not have the same efficacy. If not the IDIX stock will sink and novartis will lose a big chunk of their investment.<

Not really a Catch-22 – NVS’ investment in IDIX is not material to NVS’ financial well-being. If NVS thinks the drug is commercially unworkable, they will pass on it and not worry one iota about their equity stake in IDIX.